Stay updated with breaking news from Daniel Vitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug’s Neuroprotective Potential 17.11.2022 / 12:30 CET/CEST The issuer is solely responsible for th...
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in November and December 10.11.2022 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Investor and Scientific Conferences ...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...